Viracta Therapeutics Inc (VIRX)

Jan 28, 2025

Viracta Therapeutics strikes deal to avoid default - MSN

Jan 28, 2025

Jan 25, 2025

Viracta Therapeutics strikes deal to avoid default By Investing.com - Investing.com South Africa

Jan 25, 2025

Jan 24, 2025

Viracta Therapeutics (VIRX) Stock Price, News & Analysis - MarketBeat

Jan 24, 2025

Jan 17, 2025

Viracta Therapeutics faces Nasdaq delisting over audit issue By Investing.com - Investing.com Canada

Jan 17, 2025

Jan 17, 2025

Viracta Therapeutics faces Nasdaq delisting over audit issue - MSN

Jan 17, 2025

Jan 07, 2025

BioLineRx announces $10M registered direct offering; shares tumble - MSN

Jan 07, 2025

Jan 02, 2025

Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options - News & Insights

Jan 02, 2025

Dec 30, 2024

North American Morning Briefing : Boeing Stock -2- - Marketscreener.com

Dec 30, 2024

Dec 28, 2024

Viracta Therapeutics (NASDAQ:VIRX) Given “Neutral” Rating at Rodman & Renshaw - Defense World

Dec 28, 2024

Dec 27, 2024

Rodman & Renshaw Downgrades Viracta Therapeutics (VIRX) - MSN

Dec 27, 2024

Dec 27, 2024

Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure - Yahoo Finance

Dec 27, 2024

Dec 27, 2024

Deal Dispatch: Party City Wraps Up, Big Lots Goes Bust, The Container Store Continues - Benzinga

Dec 27, 2024

Dec 27, 2024

Castellum, Viracta Therapeutics And 3 Stocks To Watch Heading Into Friday (CORRECTED) - Benzinga

Dec 27, 2024

Dec 27, 2024

ServiceTitan initiated, Viracta downgraded: Wall Street's top analyst calls - Yahoo Finance

Dec 27, 2024

Dec 27, 2024

Viracta stock falls on strategic review (VIRX:NASDAQ) - Seeking Alpha

Dec 27, 2024

Dec 27, 2024

Masimo To Rally More Than 13%? Here Are 5 Top Analyst Forecasts For Friday - Benzinga

Dec 27, 2024

Dec 27, 2024

Constellium, Viracta Therapeutics And 3 Stocks To Watch Heading Into Friday - Benzinga

Dec 27, 2024

Dec 26, 2024

Viracta Therapeutics, Inc. Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives - Marketscreener.com

Dec 26, 2024

Dec 26, 2024

Viracta Therapeutics Ends Naval-1 Clinical Trial and Is Exploring Strategic Alternatives - MarketWatch

Dec 26, 2024

Dec 26, 2024

Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives - GlobeNewswire

Dec 26, 2024

Dec 26, 2024

Viracta Therapeutics (VIRX) Halts Phase 2 NAVAL-1 Trial, Explores Strategic Alternatives Amid Resource Conservation - StockTitan

Dec 26, 2024

Dec 17, 2024

Viracta Therapeutics' SWOT analysis: stock focus narrows amid pipeline shift - Investing.com

Dec 17, 2024

Dec 15, 2024

Viracta Therapeutics, Inc. (NASDAQ:VIRX) Short Interest Update - Defense World

Dec 15, 2024

Dec 13, 2024

Viracta Therapeutics Inc (NASDAQ: VIRX) Has Great Upside Potential - Stocks Register

Dec 13, 2024

Dec 11, 2024

Viracta Therapeutics' SWOT analysis: focused strategy reshapes stock outlook By Investing.com - Investing.com Australia

Dec 11, 2024

Dec 11, 2024

Epstein-Barr Virus (EBV) Market A Deep Dive into Current - openPR

Dec 11, 2024

Dec 10, 2024

Viracta Therapeutics' SWOT analysis: focused strategy reshapes stock outlook - Investing.com

Dec 10, 2024

Dec 01, 2024

Viracta Therapeutics faces Nasdaq delisting over non-compliance By Investing.com - Investing.com Australia

Dec 01, 2024

Dec 01, 2024

Viracta Therapeutics faces Nasdaq delisting over non-compliance - Investing.com

Dec 01, 2024

Nov 23, 2024

Viracta Therapeutics faces Nasdaq delisting risk - Investing.com India

Nov 23, 2024

Nov 23, 2024

Viracta Therapeutics faces Nasdaq delisting risk By Investing.com - Investing.com Canada

Nov 23, 2024

Nov 22, 2024

Volkswagen Ag ADR (VWAGY) QuotePress Release - The Globe and Mail

Nov 22, 2024

Nov 22, 2024

Contrasting ALX Oncology (NASDAQ:ALXO) & Viracta Therapeutics (NASDAQ:VIRX) - Defense World

Nov 22, 2024

Nov 17, 2024

Royal Bank of Canada Cuts Viracta Therapeutics (NASDAQ:VIRX) Price Target to $2.00 - Defense World

Nov 17, 2024

Nov 15, 2024

VIRX stock touches 52-week low at $0.15 amid market challenges - Investing.com UK

Nov 15, 2024

Nov 14, 2024

Viracta Therapeutics Highlights Strategic Focus and Financials - TipRanks

Nov 14, 2024

Nov 14, 2024

Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews

Nov 14, 2024

Nov 13, 2024

Sunesis: Q3 Earnings Snapshot - mySA

Nov 13, 2024

Nov 13, 2024

Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024

Nov 13, 2024

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Nov 13, 2024

Nov 13, 2024

Head and Neck Cancer Market Expected to Reach $9.07 Billion by 2030, Growing at 16.2% CAGR As Revealed In N... - WhaTech

Nov 13, 2024

Nov 13, 2024

Natural Killer T-Cell Lymphoma Market 2024 Projections, - openPR

Nov 13, 2024

Nov 08, 2024

Viracta Thera pins hopes on lead lymphoma program - The Pharma Letter

Nov 08, 2024